Product news

Share this article:

The FDA has approved Evithrom (human thrombin), a blood-clotting protein used to help control bleeding during surgery. Evithrom is the first human thrombin approved since 1954 and is the only product currently licensed. It is derived from human plasma obtained from carefully screened and tested US donors and has undergone steps to further reduce the risk for transfusion-transmitted diseases. Evithrom is manufactured by Omrix Biopharmaceuticals of Ramat Gan, Israel, and will be distributed by Johnson & Johnson Wound Management, a division of Ethicon, in Somerville, NJ.

Ipsen has announced that the FDA has approved Somatuline Depot (lanreotide) Injection in 60, 90 and 120 mg. versions. Somatuline Depot is indicated for the long-term treatment of the hormonal disorder acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. Somatuline Depot will be available in a pre-filled syringe eliminating any need for reconstitution and thus enabling freedom of easy administration to patients.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.